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Abstract: High circulating HDL concentrations and measures of various HDL functions are inversely
associated with cardiovascular disease (CVD) risk. Paraoxonase 1 (PON1) contributes to many of
the athero-protective functions of HDL, such as promoting the reverse cholesterol transport process
and reducing the levels of oxidized LDL. PON1 activities are influenced by several factors, the most
important being diet and genetic polymorphisms. Reported data from randomized controlled trials
have shown that anthocyanin consumption increased PON1 activity. However, the underlying
molecular mechanisms by which anthocyanins increase PON1 activity are not understood. Therefore,
the aim of this research was to investigate the ability of anthocyanins and their metabolites to
increase PON1 gene expression and/or enzyme activities as potential mechanisms. The effect of
the two predominant dietary anthocyanins and 18 of their recently identified microbial metabolites
including their phase-II conjugates on PON1 gene expression was studied using a PON1-Huh7
stably-transfected cell line and reporter gene assay. The effects of these compounds on PON1
arylesterase and lactonase activities were investigated using two isoforms of the PON1 enzyme that
are the phenotypes of the 192Q/R polymorphism. None of the compounds caused even modest
changes in PON1 promoter activity (p ≥ 0.05). Further, none of the compounds at physiological
concentrations caused any significant changes in the arylesterase or lactonase activity of either
of the iso-enzymes. Cyanidin reduced the lactonase activity of the PON1-R192R enzyme at high
concentrations (−22%, p < 0.001), but not at physiologically achievable concentrations. In conclusion,
none of the data reported here support the notion that anthocyanins or their metabolites affect PON1
transactivation or enzyme activities.
Keywords: polyphenols; flavonoids; phase-II metabolism; anthocyanin metabolites; human
metabolism; lactonase activity; arylesterase activity; promoter activity; single nucleotide
polymorphism; protocatechuic acid; phloroglucinaldehyde
1. Introduction
Many epidemiological and clinical studies suggest that the consumption of anthocyanin-rich fruit
and vegetables is associated with favorable improvements in lipid profiles, specifically with reductions
in LDL cholesterol and increases in HDL cholesterol [1–4]. High levels of circulating HDL cholesterol
Nutrients 2019, 11, 2872; doi:10.3390/nu11122872 www.mdpi.com/journal/nutrients
Nutrients 2019, 11, 2872 2 of 18
are inversely correlated with the incidence of cardiovascular disease (CVD), mainly coronary heart
disease (CHD) [5–7]. However, more recent studies have suggested that the relationship between
HDL and CVD markers extends beyond the concentration of HDL alone and that the function of HDL
may be more important than HDL concentration in protecting against CVD [8–11]. HDL possesses a
number of atheroprotective functions such as mediation of cholesterol efflux from cholesterol-loaded
cells, protection against oxidation and inflammation, and promotion of nitric oxide synthesis [12].
This protective effect is largely attributed to enzymes associated with HDL, including paraoxonase 1
(PON1) [13].
PON1 is an HDL-associated enzyme secreted by the liver and found to have significant
anti-oxidative and anti-inflammatory properties though its lactonase, peroxidase, and esterase
activities [14]. The anti-atherogenicity of PON1 is thought to be related to its ability to hydrolyze
oxidized cholesteryl esters and oxidized phospholipids and degrade hydrogen peroxide, thus protecting
lipoprotein particles from any further oxidative modification [15].
Polymorphisms in the PON1 gene can affect enzyme activities, stability, and the anti-atherogenicity
of the PON1 enzyme [16–20]. Among the numerous PON1 polymorphisms in humans, the Q192R
and L55M polymorphisms are the ones most associated with lipoprotein oxidation and CHD risk,
and there is evidence that these polymorphisms explain a significant proportion of the differences in
PON1 activity between individuals [21]. People with the 192-Q/Q genotype gain greater protection
against CVD compared to those with 192-R/R PON1. The 192-Q/Q PON1 enzyme is more potent
in decreasing the levels of oxidized lipids in human atherosclerotic lesions than the 192-R/R PON1
enzyme [22,23]. The PON1 L55M polymorphism has also been associated with variation in serum
PON1 activity but has a weaker effect [24]. PON1 polymorphisms also affect the enzyme’s substrate
specificity [25]. For instance, the 192-R/R PON1 enzyme hydrolyses paraoxon approximately nine
times faster than the 192-Q/Q, PON1 enzyme, while the opposite occurs with diazoxon and sarin
substrates [25]. Therefore, ignoring the genetic variant could lead to a false interpretation, especially,
when substrates that are strongly influenced by polymorphisms such as paraoxon are being used [26].
Therefore, it is recommended to compare PON1 levels within each different genotype/phenotype group.
Anthocyanins have been reported to increase PON1 activity. A 17.4% mean increase in PON1
arylesterase was reported in response to a 24-week intervention with a mixture of purified anthocyanins
extracted from bilberry and blackcurrant (Medox™) in human participants with hypercholesterolemia
compared to placebo [27]. A similar effect on serum PON1 was reported for participants who had
consumed pomegranate juice for two weeks compared to a control beverage [28]. In addition, treatment
of PON1-Huh7 cells with polyphenol-rich and anthocyanin-rich purple sweet potato fractions was
reported to cause significant induction of PON1 promoter transactivation [29]. Other polyphenols
such as quercetin, resveratrol, and catechin have also been reported to modulate PON1 activity and
gene expression in vivo and in vitro [30–35].
There is growing evidence that anthocyanins are subjected to extensive metabolism, especially by
the gut microbiota, producing a wide range of metabolites [36]. After consumption of penta-13C-labelled
cyanidin-3-glucoside (C3G), most of the given dose was recovered as breakdown products (A- and
B-ring-derived phenolics), while only minor quantities of intact C3G were recovered [37,38]. Of the 35
metabolites identified in human plasma, urine, and feces in this study, hippuric acid, vanillic acid,
ferulic acid, 4-hydroxybenzaldehyde, and vanillic acid sulphate were the predominant metabolites [38].
The much higher concentrations in blood and the relative stability of anthocyanin metabolites suggest
that the high bioactivity of anthocyanins is more likely to be mediated by their metabolites rather than
the parent compounds. However, the biological activity of the majority of these metabolites has not
been investigated.
Therefore, the aim of this study was to investigate the effects of two predominant dietary
anthocyanins (C3G and delphindin-3-glucoside (D3G)), and their degradation products including
their phase-II conjugates on PON1 gene expression and PON1 arylesterase and lactonase activities.
The potential for anthocyanins or their metabolites to induce PON1 expression was determined using
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a reporter gene assay and the effects on enzyme activities assessed using isolated PON1 isoenzymes
corresponding to the major functional SNPs in humans.
2. Materials and Methods
2.1. Reporter Gene Assay
2.1.1. Cell Culture
The effect of anthocyanins and their metabolites on PON1 gene expression was evaluated using a
reporter gene assay (Bioluminescence firefly luciferase assay) in cultured hepatocytes. PON1-Huh7
was a Huh7 liver hepatoma cell line that had been stably transfected with a reporter plasmid containing
1009 bp [–1013, –4] of the PON1 gene promoter cloned into the firefly luciferase reporter vector pGL3
basic [30,39].
PON1-Huh7 cells were kindly provided by Dr. X. Coumoul and Dr. Robert Barouki, French
National Institute of Health and Medical Research (INSERM), France. PON1-Huh7 cells were
maintained following the protocol as previously described [39]. Briefly, PON-Huh7 cells were
cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with fetal bovine serum
(FBS) 10% (v/v), penicillin (100 U/mL) and streptomycin (100 µg/mL), glutamine (2 mM), and G418
disulphate (100 µg/mL) (Sigma-Aldrich) at 37 ◦C in 5% CO2 until reaching 80%–90% confluency, with
the media changed every two days. The cells were then detached by adding trypsin-EDTA for 2–3
min at 37 ◦C. A complete DMEM that contained 10% FBS was then added to inhibit the trypsin.
The trypsinized cell suspension was collected and the cells were either split or seeded for treatments.
In 24-well plates, cells were seeded at an initial density of 0.15 × 106 cells/well and left to attach for 24 h.
2.1.2. Treatments
Following seeding the cells, the media was removed and new pre-warmed media containing
anthocyanins treatment was added to the appropriate wells and incubated at 37 ◦C, 5% CO2 for 48 h.
The treatments were C3G, D3G, and their major known human metabolites (reported elsewhere [38])
together with their potential/predicted metabolites at 1 and 10 µM. The cells were also treated
with phase-II conjugates of protocatechuic acid (PCA) and gallic acid, namely PCA-glucuronides
(PCA-GlcAs, including PCA-3-glucuronid (PCA-3-GlcA) and PCA-4-glucuronide (PCA-4-GlcA), each
at 1 µM), PCA-sulphates (PCA-sulphs, including PCA-3-sulphate (PCA-3-Sulph) and PCA-4-sulphate
(PCA-4-Sulph), each at 1 µM), gallic acid glucuronides (GA-GlcAs, including gallic acid-3-glucuronide
(GA-3-GlcA) and gallic acid-4-glucuronide (GA-4-GlcA), each at 1 µM), and methylgallates (MethGA,
including 3-O-methylgallic acid (3MethGA) and 4-O-methylgallic acid (4MethGA), each at 1 µM).
Figure 1 depicts the chemical structure of these metabolites. In order to investigate the interaction
between anthocyanin metabolites, the cells were treated with two different mixtures of anthocyanin
metabolites, PCA-Mix and GA-Mix. PCA-Mix contains C3G, PCA, PCA-4-GlcA, PCA-3-GlcA,
PCA-3-Sulph, and PCA-4-Sulph, at 1 µM each. GA-Mix contains D3G, gallic acid, GA-3-GlcA,
GA-4-GlcA, 3MethGA, and 4MethGA, at 1 µM each. The vehicle control was DMSO with final
concentration of 0.1%. Curcumin (20 µM) (Fisher Scientific) served as a positive control alongside the
anthocyanins and their metabolite treatments. Treatments were conducted in quadruplicate and the
experiments were repeated at least two times. The tested compounds were purchased from Sigma
Aldrich, syringic acid was purchased from Alfa Aesar, and phloroglucinol was purchased from Across
Organics. PCA conjugates and gallic acid conjugates were synthesized in-house [40]. After treatment,
the luciferase activity was measured as a marker of PON1 promoter activity.
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Figure 1. The chemical structures of cyanidin-3-O-glucoside, delphinidin-3-O-glucoside, and their 
known and potential metabolites: phloroglucinaldehyde (PGA), protocatechuic acid (PCA), 4-
hydroxybenzaldehyde (4HBA), PCA-3-sulphate (PCA-3-sulph), PCA-4-sulphate (PCA-4-Sulph), 
PCA-3-glucuronide (PCA-4-GlcA), PCA-4-glucuronide (PCA-4-GlcA), 3-O-methylgallic acid 
(3MethGA), 4-O-methylgallic acid (4MethGA), gallic-3-glucuronide (GA-4-GlcA), and gallic acid-4-
glucuronide (GA-4-GlcA). AccelrysDraw (version 4.2 for windows) was used to draw the chemical 
structures. 
Figure 1. The chemical structures of cyanidin-3-O-glucoside, delphinidin-3-O-glucoside, and
their known and potential metabolites: phloroglucinaldehyde (PGA), protocatechuic acid (PCA),
4-hydroxybenzaldehyde (4HBA), PCA-3-sulphate (PCA-3-sulph), PCA-4-sulphate (PCA-4-Sulph),
PCA-3-glucuronide (PCA-4-GlcA), PCA-4-glucuronide (PCA-4-GlcA), 3-O- ethylgallic acid
(3 ethGA), 4-O-methylgallic acid (4MethGA), gallic-3-glucuronide (GA-4-GlcA), and gallic
acid-4-glucuronide (GA-4-GlcA). AccelrysDraw (version 4.2 for windows) was used to draw the
chemical structures.
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2.1.3. Luciferase Assay
Luciferase activity was measured using the Luciferase Assay System (Promega, Hampshire, UK,
Cat# E1500) according to the manufacturer’s instructions. Briefly, after 48 h treatment, the media was
removed, and the cell layer was washed twice with cold calcium- and magnesium-free PBS. The lysis
buffer was then added to the cell layer and the cells were scraped. Immediately, the lysate was collected
and centrifuged for 2 min at 12,000 XG at 4 ◦C. After that, in 96-well white plates, 100 µL of luciferase
assay reagent were added to 20 µL cell lysate. The luminescence was immediately measured over 20 s
using a plate reader, FLUROstar Optima (BMG labtech, UK).
The plate reader is capable of injecting the reagent automatically and can perform multi-well
readings. The luminescence was expressed as total light intensity which was collected over 20 s. Results
were normalized to the total cell protein content. The total protein in each sample was determined
using the bicinchoninic acid (BCA)-Reducing Agent Compatible assay as per the manufacturer’s
protocol (Thermofisher, Paisley, UK, Cat# 23252).
2.1.4. PON1 Promoter Activity Calculation
First, the light intensity which reflects the promoter activity was normalized to the total protein
content in the cell lysate.
Promoter activity = Total light intensity/total protein content (µg/mL).
Then, the fold change of PON1 promoter activity was calculated relative to the control (DMSO).
2.1.5. PON1 Enzyme Activities
The direct effect of anthocyanins on PON1 activities was measured using a commercially available
purified PON1 that phenotyped into two phenotypes based on Q192R polymorphism. PON1 phenotype
QQ (PON-QQ) and phenotype RR (PON-RR) were purchased from ZeptoMetrix (Buffalo NY, USA,
Cat# 0801384). The treatments were prepared as described earlier and were diluted in the assay
buffer. Arylesterase and lactonase PON1 activities were measured using colourimetric assays as
described below.
2.1.6. PON1 Arylesterase
PON1 arylesterase activity was quantified by measuring the hydrolysis rate of p-nitrophenyl
acetate (a colorless substrate) into p-nitrophenol (that has a yellow color) and measuring the increase
in absorbance using a spectrophotometer [41]. PON1 arylesterase activity was measured as described
elsewhere [13,42,43]. First, PON-RR and PON-QQ were diluted in assay buffer consisting of 20 mM
Tris-HCl buffer, pH = 8 and 1 mM CaCl2, just prior to conducting the assay. The dilution factors
for PON-RR and PON-QQ were 10- and 15-fold, respectively. The assay was developed with a final
volume of 200 µL in 96-well polystyrene plate. Here, 20 µL of diluted enzyme and 20 µL of treatment
were mixed together with 140 µL pre-warmed assay buffer. The plate was then sealed to prevent
evaporation and incubated at 37 ◦C for 10 min. Quickly, 20 µL of diluted substrate was added to
the previous reaction mixture and the increase in absorbance was measured immediately at 410 nm
for 10 min using FLUROstar Optima (BMG labtech, UK). The final concentrations of reactants were
1% PON-RR (0.63 U/mL)/0.7% PON-QQ (1.3 U/mL), 1 mM p-nitrophenyl acetate, and 1 or 10 µM
anthocyanin treatments. The final concentration of DMSO was 0.1% in all treatments. The control
treatment was enzyme treated with DMSO at final concentration of 0.1%. The slope of the reaction rate
was calculated using the instrument software. Blanks without enzymes or treatments were used to
correct for the spontaneous nonenzymatic hydrolysis of p-nitrophenyl acetate by subtracting blanks
from the hydrolysis rate of treatments. The % of change was calculated relative to the control as
following:
% o f Change =
hydrolysis rate o f treatment− hydrolysis rate o f control
hydrolysis rate o f control
× 100
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Treatments were conducted in triplicates and the experiments were repeated at least two times.
The purity of the enzymes was determined by measuring the activity of enzymes with 100 µM of
2-hydroxyquinoline (2-HQ), the PON1-potent inhibitor (Sigma-Aldrich, Dorset, UK, Cat# 270873).
2.1.7. PON1 Lactonase
PON1 lactonase activity was measured spectrophotometrically by monitoring the hydrolysis of
the synthetic lipolactone substrate, 5-thiobutyl butyrolactone (TBBL) [44,45]. Lactonase activity was
measured as described previously [46,47]. Briefly, PON-RR and PON-QQ were diluted to 50- and
80-fold, respectively, in the assay buffer that consisted of 50 mM Tris-HCl, 1 mM CaCl2, 50 mM NaCl,
and pH = 8. Using 96-well polystyrene plates, 20 µL of enzyme and 20 µL of treatment were mixed
together with 60 µL pre-warmed assay buffer, and then 50 µL of 5,5′-dithiobis (2-nitrobenzoic acid)
(DTNB, 4 mM) were mixed with the reaction mixture. The plate was sealed to prevent evaporation
and incubated for 10 min at 37 ◦C. A solution of TBBL (2 mM) was prepared in pre-warmed assay
buffer contain 2% acetonitrile just before use. After that, 50 µL of TBBL (2 mM) was added to the
reaction mixture and the absorbance was measured immediately at 412 nm using a FLUROstar Optima
plate reader (BMG labtech, UK). The final volume was 200 µL and the concentrations of reactants
were 0.2% PON-RR (0.13 U/mL)/0.125% PON-QQ (0.23 U/mL), 1 mM DTNB, 0.5 mM TBBL, and 1
or 10 µM treatments. The lactonase activity was calculated as previously described for arylesterase.
Treatments were conducted in quadruplicate and the experiments were repeated at least two times.
The purity of the enzymes was determined by measuring the activity of enzymes with 100 µM of
2-hydroxyquinoline (2-HQ).
2.1.8. Statistical Analysis
All data and statistics were analyzed using GraphPad Prism (version 5.04 for Windows, GraphPad
Software, La Jolla California USA, (https://www.graphpad.com/). All values are given as means ± SD.
Any statistical difference between the groups was determined with one-way ANOVA coupled with
Dunnett’s multiple comparison test comparing all sample groups to control (DMSO 0.1%). Values of
p ≤ 0.05 were considered significant.
3. Results
3.1. Effects of Anthocyanins and Their Metabolites on PON1 Promoter Activity
The effect of anthocyanins and their metabolites on PON1 gene expression was investigated by
measuring activation of the PON1 promoter in PON1-Huh7 stably transfected cells. As shown in
Figure 2A, C3G and D3G did not cause any significant change in PON1 promoter activity compared
to the control (DMSO) at either 1 or 10 µM; C3G treatment resulted in a small increase but this
was not significant (p ≥ 0.05). Similarly, a large number of anthocyanin metabolites were tested,
including known metabolites of anthocyanins that were reported previously from the study that used
penta-13C-labelled C3G [38] (Figure 2B) and a series of predicted anthocyanin metabolites. None
of these metabolites (Figure 2C) or the phase-II-conjugates (Figure 2D) that were tested had any
significant effect on PON1 promoter activity. In contrast to what we had predicted, syringic acid,
cyanidin, 5-HFA, and hippuric acid reduced promoter activity by between 10% and 20%, although
the changes were not significant (Figure 2C). In contrast, curcumin (the positive control) significantly
increased PON1 promoter activity by 5.3-fold (Figure 2A–D, p ≤ 0.001) which was consistent with
previous reports [29,39,48]. This demonstrates that the model is functioning properly and sensitive to
treatments. Although these data showed that anthocyanins and their metabolites did not significantly
alter the promoter activity of PON1, it is possible that they may interact with PON1 in a different way,
for example by activating the enzyme and increasing its activities. Therefore, the effect of anthocyanins
and their metabolites on PON1 enzyme activities were investigated.
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Figure 2. Effect of anthocyanin parent compounds (A), their known human metabolites (B), their
potential/predicted metabolites (C), and phase-II conjugates (D) on paraoxonase 1 (PON1) promoter
activity. A reporter gene assay was used to measure the promoter activity in PON1-Huh7 cells.
The fold change was calculated relative to control (DMSO). Data are shown as means ± SD.
*** p ≤ 0.001 as compared to control using one-way ANOVA coupled with Dunnett’s multiple
comparison test. Treatments were as follows: cyanidin-3-glucoside (C3G), delphinidin-3-glucoside
(D3G), phloroglucinaldehyde (PGA), protocatechuic acid (PCA), 4-hydroxybenzaldehyde (4HBA),
5-hydroxyferulic acid (5HFA), PCA-glucuronides (PCA-GlcAs), PCA-sulphates (PCA-Sulphs) PCA-Mix
(C3G, PCA, and PCA conjugates), gallic acid glucuronides (GA-GlcAs), methylgallates (MethGA),
GA-Mix (D3G, gallic acid and gallic acid conjugates), and curcumin (20 µM) which served as a positive
control. Treatments were conducted in quadruplicate and the experiments were repeated at least
two times.
3.2. Effect of Anthocyanins and Their Metabolites on PON1 Activities
3.2.1. Establishing a Fit-for-Purpose Enzyme Assay
To avoid inaccurate enzyme activity measurements, the reaction rate should be measured within
the linear stage of the enzyme reaction. To establish a linear enzyme reaction, serial dilutions of
PON-RR and PON-QQ enzymes were tested with p-nitrophenyl acetate (the substrate for arylesterase)
and TBBL (the substrate for lactonase). A concentration of 1% PON-RR (0.63 U/mL) and 0.7% PON-QQ
(1.3 U/mL) enzymes resulted in a linear reaction of arylesterase (Figure 3A), while the linearity of the
lactonase enzyme reaction was achieved with 0.2% PON-RR (0.13 U/mL) and with 0.125% PON-QQ
(0.23 U/mL) (Figure 3B). The linear regression coefficient (R2) was about 0.99, which is very close to
1 for both arylesterase and lactonase, meaning that the reaction is linear at these concentrations of
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PON-RR and PON-QQ. In addition, the reaction remained linear for at least 16 min for both reactions
(Figure 3A,B). To make sure that the model was working and to validate that the commercial enzyme
does not contain any other esterases rather than PON1, the arylesterase and lactonase activities were
measured in the presence and absence of 2-hydroxyquinoline (2-HQ), a potent inhibitor of PON1.
It was found that 2-HQ resulted in about 97.5% inhibition for PON-RR and PON-QQ for both activities,
confirming the suitability of the model for this purpose of study (Figure 3A,B).
Nutrients 2019, 10, x FOR PEER REVIEW  8 of 18 
concentration of the PON-RR or PON-QQ enzymes (Figure 4A). Likewise, none of the tested 
metabolites either the known, the potential or the phase-II conjugates affected the arylesterase 
activity, except for gallic acid, phloroglucinol, and cyanidin (Figure 4B–D). 
Gallic acid at the higher conce tration (10 µM) sig ifica tly inc eas d PON-QQ a yleste ase (but 
not PON-RR  by 9% compared o the c ntrol (Figu e 4B, p ≤ 0.001). Similarly, phl roglucinol at both 
1 and 10 µM increased PON-QQ (but not PON-RR) but by only 4% (Figure 4C, p ≤ 0.001). On he other 
hand, the high concentratio  of cya idin (10 µM) but not the low concentration slightly decreased 
PON-RR by 6% (Figure 4C, p ≤ 0.001). Althoug  statistically significant effects were bserved for 
gallic ac d, p loroglucinol and cyanidin, the effects were very modest. 
 
Figure 3. PON1 enzyme reaction progress curve for arylesterase (A) and lactonase (B). For 
arylesterase, the substrate was added to the 1% PON1 R192R phenotype (PON-RR) and to the 0.7% 
PON1 Q192Q phenotype (PON-QQ) with and without PON1 inhibitor (100 µM 2-hydroxyquinoline 
(2-HQ)). For lactonase, the substrate was added to 0.2% PON-RR and 0.125% PON-QQ with and 
without 100 µM 2-HQ. The enzymes were diluted in assay buffer. The absorbance was recorded over 
16 min. R2 = linear regression coefficient. R2 was calculated using Excel software 2016.  
3.2.3. Effect of Anthocyanins and Their Metabolites on PON1 Lactonase Activity. 
As shown in Figure 5A–D, a few of the tested anthocyanins and their metabolites caused 
significant changes in PON1 lactonase activity, although the changes were not substantial. C3G had 
a very small but significant effect on the enzyme activity of both PON-RR and PON-QQ phenotypes. 
However, PON-QQ phenotype lactonase activity was affected more with increases of 11% and 9% at 
concentrations of 1 and 10 µM, respectively (p ≤ 0.001), while the lactonase activity of PON-RR 
increased by 6% and 8% at concentrations of 1 and 10 µM of C3G, respectively (p ≤ 0.001, Figure 5A). 
On the other hand, only a modest increase (5%) in PON-RR lactonase activity was observed with D3G 
(1 µM) (Figure 5A, p ≤ 0.001). Moreover, most of the tested anthocyanin metabolites did not cause 
significant changes, except for small changes in response to treatment with gallic acid, vanillic acid, 
and ferulic acid (Figure 5B, p ≤ 0.001). 
The only substantial effect was observed with cyanidin (Figure 6A and B). Unexpectedly, 
cyanidin at 10 µM significantly decreased PON-RR lactonase activity but not PON-QQ by 22% (p ≤ 
0.001), while the lower concentration of cyanidin did not cause a change (Figure 6A). This finding 
was confirmed by doing a dose-response curve for cyanidin with PON-RR enzyme. As shown in 
Figure 6B, cyanidin decreased lactonase activity of PON-RR in a dose-dependent manner with about 
30% reduction observed at the highest concentration (20 µM cyanidin). However, the lower more 
physiological concentrations of cyanidin (0.1, 0.5 µM, 1 µM) did not affect PON-RR activity. On the 
other hand, PON-QQ appeared to respond differently when treated with cyanidin: The low 
concentration of cyanidin (1 µM) but not the high one slightly increased PON-QQ by 8% (Figure 6A, 
p ≤ 0.001). However, it should be taken into account that the magnitude of effects where statistically 
significant effects were detected were modest (typically 4%−11%). 
Figure 3. PON1 enzyme reaction progress curve for arylesterase (A) and lactonase (B). For arylesterase,
the substrate was added to the 1% PON1 R192R phenotype (PON-RR) and to the 0.7% PON1
Q192Q phenotype (PON-QQ) with and without PON1 inhibitor (100 µM 2-hydroxyquinoline (2-HQ)).
For lactonase, the substrate was added to 0.2% PON-RR and 0.125% PON-QQ with and without 100 µM
2-HQ. The enzymes were diluted in assay b ffer. The absorbance was recorded over 16 min. R2 =
linear regression co fficient. R2 was calculated using Excel software 2016.
3.2.2. Effect of Anthocyanins and Their etabolites on PO 1 Arylesterase Activity
In this study, the direct effect of anthocyanin parent compounds and their metabolites on
PON1 arylesterase activity was examined using two different phenotypes, PON-RR and PON-QQ
(Figure 4A–D). The findings demonstrated that neither C3G or D3G affected the arylesterase activity at
either concentration of the PON-RR or PON-QQ enzymes (Figure 4A). Likewise, none of the tested
metabolites either the known, the potential or the phase-II conjugates affected the arylesterase activity,
except for gallic acid, phloroglucinol, and cyanidin (Figure 4B–D).
Gallic acid at the higher concentration (10 µM) significantly increased PON-QQ arylesterase (but
not PON-RR) by 9% compared to the control (Figure 4B, p ≤ 0.001). Similarly, phloroglucinol at both 1
and 10 µM increased PON-QQ (but not PON-RR) but by only 4% (Figure 4C, p ≤ 0.001). On the other
hand, the high concentration of cyanidin (10 µM) but not the low concentration slightly decreased
PON-RR by 6% (Figure 4C, p ≤ 0.001). Although statistically significant effects were observed for gallic
acid, phloroglucinol and cyanidin, the effects were very modest.
3.2.3. Effect of Anthocyanins and Their Metabolites on PON1 Lactonase Activity
As shown in Figure 5A–D, few of the ested anthocyanins an their metaboli es caused s gnifican
chang s in PON1 lactonase activity, although the cha ges were not substantial. C3G had a very small
but ignifi nt effect on the enzyme activity of both PON-RR and PON-QQ phenotypes. However,
PON-QQ phenotype lactonase activity was affected more with increases of 11% and 9% at co centrati ns
of 1 a d 10 µM, respectively (p ≤ 0.001), while the lactonase a tivity of PON-RR increased by 6%
and 8% at c nc nt ations of 1 and 10 µM f C3G, respectively (p ≤ 0.001, Figure 5A). On the other
ha d, o ly a modest increas (5%) in PON-RR la tonase activity was observed with D3G (1 µM)
(Figure 5A, p ≤ 0.001). Moreover, most of the tested anthocyanin metabolites did not cause significant
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changes, except for small changes in response to treatment with gallic acid, vanillic acid, and ferulic
acid (Figure 5B, p ≤ 0.001).
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Figure 4. Effect of anthocyanins parent compounds (A), their known human metabolites (B), their
potential/predicted metabolites (C), and phase-II-conjugates (D) on arylesterase activity of PON1
R192R (PON-RR) and Q192Q (PON-QQ) phenotypes. The % of change in activity was calculated
relative to the control (DMSO). Data are shown as means ± SD. ** p ≤ 0.01 and *** p ≤ 0.001 as
compared to control using one-way ANOVA coupled with Dunnett’s multiple comparison test.
Treatments were: cyanidin-3-glucoside (C3G), delphinidin-3-glucoside (D3G), phloroglucinaldehyde
(PGA), protocatechuic acid (PCA), 4-hydroxybenzaldehyde (4HBA), 5-hydroxyferulic ci (5HFA),
PCA-glucuronides (PCA-GlcAs), PCA-sulphates (PCA-Sulphs) PCA-Mix (C3G, PCA, and PCA
conjugates), gallic acid glucuronid s (GA-GlcAs), methylgallates (MethGA), and GA-Mix (D3G,
gallic acid, and gallic acid conjugates). Treatments were conducted in triplicates and the experiments
were repeated two times.
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Figure 5. Effect of anthocyanins parent compounds (A), their known human metabolites (B), their
potential/predicted metabolites (C), and phase-II conjugates (D) on lactonase activity of PON1
R192R (PON-RR) and Q192Q (PON-QQ) phenotypes. The % of change in activity calculated
relative to the control (DMSO). Data are shown as means ± SD. * p ≤ 0.05 and *** p ≤ 0.001 as
compared to control using one-way ANOVA coupled with Dunnett’s multiple comparison test.
Treatments were: cyanidin-3-glucoside (C3G), delphinidin-3-glucoside (D3G), phloroglucinaldehyde
(PGA), protocatechuic acid (PCA), 4-hydroxybenzaldehyde (4HBA), 5-hydroxyferulic acid (5HFA),
PCA-glucuronides (PCA-GlcAs), PCA-sulphates (PCA-Sulphs) PCA-Mix (C3G, PCA and PCA
conjugates), gallic acid glucuronides (GA-GlcAs), methylgallates (MethGA), and GA-Mix (D3G,
gallic acid and gallic acid conjugates). Treatments were conducted in triplicates and the experiments
were repeated two times.
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The only substantial effect was observed with cyanidin (Figure 6A,B). Unexpectedly, cyanidin at
10 µM significantly decreased PON-RR lactonase activity but not PON-QQ by 22% (p ≤ 0.001), while
the lower concentration of cyanidin did not cause a change (Figure 6A). This finding was confirmed by
doing a dose-response curve for cyanidin with PON-RR enzyme. As shown in Figure 6B, cyanidin
decreased lactonase activity of PON-RR in a dose-dependent manner with about 30% reduction
observed at the highest concentration (20 µM cyanidin). However, the lower more physiological
concentrations of cyanidin (0.1, 0.5 µM, 1 µM) did not affect PON-RR activity. On the other hand,
PON-QQ appeared to respond differently when treated with cyanidin: The low concentration of
cyanidin (1 µM) but not the high one slightly increased PON-QQ by 8% (Figure 6A, p≤ 0.001). However,
it should be taken into account that the magnitude of effects where statistically significant effects were
detected were modest (typically 4%−11%).Nutrients 2019, 10, x FOR PEER REVIEW  11 of 18 
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In summary, the data pres nted in this tudy do not support that anthocyanins and/or
their metabolites significantly affect PON1 gene promoter acti e the activity of PON1
enzymes. Even though some sta istically significant chan t , the changes were very
modest and probably lack clinical importance.
4. Discu sion
The overall findings of the work reported here are that neit er i t ct thocyanins and
anthocyanidins, nor their many phenolic degradation products, nor the tested phase-II-conjugates that
are the forms found in human blood caused any substantive activation of the PON1 promoter or in the
arylesterase or lactonase activities of the major isoforms of PON1.
Previously reported data from epidemiological studies and from dietary interventions with
human participants and animal models suggests that anthocyanins have the potential to decrease
the risk of CVD [49–51]. In addition, there are numerous reports describing putative biological
activities of anthocyanins based on treating, for example, cultured human cells with anthocyanins,
typically at supraphysiological concentrations. The vast majority of these reported in vitro studies have
examined only the activity of the intact form of anthocyanins and ignored the fact that anthocyanins
undergo extensive metabolism [52,53]. The unequivocal identity of the metabolites of C3G was recently
established from an elegant human feeding study that used penta-13C-labelled C3G that allowed the
Nutrients 2019, 11, 2872 12 of 18
source of the metabolites (A- or B-ring of the anthocyanidin) to be established [37,38]. In addition,
a number of metabolites of D3G and other trihydroxylated- and methylated-B ring anthocyanins have
been reported, although anthocyanin-rich dietary sources were used instead of pure or isotope-labelled
compounds [54]. The quantity of the parent (un-metabolized) 13C-C3G was very low (about 0.147 µm
of 13C-labelled C3G), while the concentration of phenolic metabolites ranged from 0.1 to 2 µM with the
cumulative concentration of metabolites reaching 10 µM [38,55] suggesting that the high bioactivity
of anthocyanins is more likely to be mediated by the metabolites. However, the activities of most of
these metabolites are unexplored or have only been reported at non- physiological doses, even up to
2.2 mM [56]. The present study, therefore, investigated for the first time the possible effects of known
and potential metabolites of C3G and D3G including their phase-II-conjugates relative to their parent
compounds at physiologically relevant concentrations, individually and in mixtures, on PON1 gene
expression and enzyme activities. In addition, the research presented in this paper is the first to the
best of our knowledge to consider the potential interaction between PON1 genotype and the dietary
anthocyanins using two different phenotypes corresponding to Q192Q and R192R genotype.
As the consumption of anthocyanins or anthocyanin-rich beverages has been reported to increase
serum PON1 activity in some human studies [27,28], the underlying hypothesis of this research was
that the increase in PON1 activity observed in these human studies was caused by the anthocyanins
or their gut microbiota metabolites interacting with PON1 gene expression or enzyme activity and
increasing the enzyme concentration and/or the enzyme activity. Here, we screened the effects not
just of the anthocyanins but also of most of the major metabolites of these compounds that are
products of gut microbiota metabolism. We aimed to connect the compounds to the effect and identify
which compounds caused the increase in activity and/or gene expression and at which concentrations.
However, the data showed that none of these compounds at physiologically relevant concentrations
(1–10 µM) caused significant changes in either PON1 promoter activity or arylesterase and lactonase
activities, regardless of the phenotype, except for some small effects that likely lack clinical importance.
The data presented here does not support the notion that there is a direct interaction between
anthocyanins and/or their metabolites with the PON1 protein or the expression of the PON1 gene. It is
possible that the increase in PON1 activity in human interventions reported previously [27,28] was
due to a secondary effect(s) of consuming anthocyanins. For example, the anthocyanins/metabolites
might cause changes in the gut microbiome or interact with other organs such as the liver, but it is the
anthocyanin-induced changes in the function of these organs that somehow caused the levels of PON1
activity to increase.
With regard effects on expression of the PON1 gene, we have only reported effects on the PON1
promotor activation using a reporter assay. We attempted to assess the effects of the treatments on
the abundance of PON1 transcripts in the classic human hepatic cell line HepG2 using qRT-PCR.
However, we were not able to detect significant expression of the PON1 gene in HepG2 cells in our
laboratory. In keeping with this observation, we were also not able to detect PON1 activity in culture
supernatants (secreted PON1, Figure S1) or cell homogenates (intracellular PON1, Figure S2). Details
of the experiments with HepG2 cells are provided in the supplementary information (Supplementary
information 1). Others have reported the use of a PON1-Huh7 transfected cell line and reported
changes in PON1 promoter activity in response to treatment with several phenolic compounds such
as curcumin, resveratrol, quercetin and isorhamnetin [30,33]. Gallic acid increased PON1 promoter
activity by 8.5-fold, however this was in response to a very high and non-physiological concentration
of gallic acid (360 µM) [57]. Here we report the effects of a physiological concentration (1 µM) and a
slightly higher concentration (10 µM), but we observed no significant effects.
Very little is currently known of the effects of direct interaction between anthocyanins or their
metabolites with the PON1 enzyme. The only available report to date is concerned with the effect of
naringin, which caused a decrease in PON1 arylesterase activity after incubation with isolated PON1
enzyme [13]; therefore all the data presented here are novel. The only other reports we are aware of
describe the effects of phenolic compounds such as resveratrol, quercetin, punicalagin and ellagic acid
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on PON-1 enzyme secretion using the Huh7 cell line [30,33]. We attempted to use the HepG2 cell line
to study the effect of treatments on enzyme secretion, but we were not able to detect any secreted or
cell-based PON1 activity in our laboratory (Supplementary information 1).
PON1 lactonase is the physiologically relevant activity that is associated with its biological
functions [26,58,59]. Impairing the lactonase activity of PON1, e.g., via mutations of its catalytic dyad,
diminished the ability of the enzyme to prevent LDL oxidation, reduced HDL-mediated cholesterol
efflux, and abolished lysophosphatidylcholine (LPC) formation from phospholipid in macrophages,
suggesting that the actual biological antiatherogenic functions of PON1 may be mediated by its
lactonase activity [59]. However, paraoxonase and arylesterase were the only activities that had been
reported previously from studies of polyphenols on PON1. To the best of our knowledge, the current
study is the first to examine the effect of anthocyanins on PON1 lactonase activity and therefore
provides new information regarding effects of anthocyanins on PON1 activity and by association with
HDL function. Although the data presented here does not support the notion that direct interactions
between anthocyanins and/or their metabolites affect the lactonase or arylesterase activity of PON1, it is
not conclusive. The purified enzyme used here is not in its native environment which would include
the presence of HDL and the ApoA1 protein, and this may affect the enzyme structural conformation
and its stability and therefore its activity [60–64]. In theory it would be possible to use instead serum as
a source of PON1. However, this may prove problematic because serum may contain other compounds
such as lipoproteins that may bind with anthocyanins and conceal or inhibit their effects [65–67].
On the other hand, cyanidin decreased PON1 lactonase activity, but at super physiological
concentrations and not at lower more physiological concentrations. However, the negative effect of
cyanidin may be physiologically unimportant. In fact, cyanidin was not detected in serum in humans
after consumption of 13C-labelled C3G. Only traces of cyanidin conjugates were detected in urine
in the same study suggesting that the existence of cyanidin in serum in concentrations higher than
0.1 µM is not achievable [38]. Furthermore, cyanidin is extremely unstable at high pH, with about 50%
instantaneous loss of the parent structure at pH 7.4, which was lower than the pH of the assay buffer
(pH = 8) used in the current study. This suggests that the reduction in PON1 lactonase activity was not
mediated directly by cyanidin but may though one or more of its intermediates [68].
As far as the authors are aware, this is the first study to report the interaction between anthocyanins
and their metabolites, PON1 genotype and PON1 activities. None of the previous reports that
investigated the effects of anthocyanins and other polyphenols on PON1 activities have considered
the association between PON1 polymorphisms and its activity [27,28]. Here we used two enzyme
isoenzymes that correspond with two functional Q192R polymorphisms, PON-QQ and PON-RR.
At high concentrations, cyanidin decreased PON1 lactonase activity of the PON-RR isoenzyme,
but it increased the lactonase activity of PON-QQ. These observations support the notion that
individuals respond differently to treatment according to their PON1 genotype, and therefore the
genetic variance should be taken into account. Although both phenotypes responded similarly to the
other anthocyanins/metabolites, this does not preclude that these metabolites may interact and affect
the enzyme activities with other genotypes other than the Q192R genotype. In a previous nutrigenomic
study, a significant association between anthocyanin intake and increased HDL levels was reported in
participants with some PON1 genotypes but not with others [69]. The study investigated interactions
between SNPs in the PON1 gene and polyphenols intake on HDL and other biomarkers of CVD
risk. Of 18 independent tagging SNPs that were tested, four SNPs (rs854549, rs854552, rs854571, and
rs854572) showed a significant association with increased circulating HDL levels in people consuming
higher quantities of polyphenols and anthocyanins [69]. At present there is no commercial source of
purified isoenzymes corresponding to these genotypes to understand how these genotypes respond
to anthocyanin treatments. However, undertaking a human intervention with large population and
categorizing the participants into different group based on their genotype and studying the enzyme
activities after anthocyanin intervention would provide a better insight into the interaction between
anthocyanins, PON1 activities and PON1 genotype.
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Although the data presented in this report are novel, there are several limitations. Measuring the
effects of the polyphenols on promoter activity rather than gene expression (transcript levels) is one
weakness. The reporter assay may not faithfully recapitulate the native chromosome environment [70].
The treatments may affect the stability of mRNA or other posttranscriptional regulators of the PON1
gene without affecting the promotor activity, which will not be detected using the reporter assay.
In addition, the effects of the anthocyanins and their metabolites on enzyme secretion has not been
investigated in the current study due the authors not having a suitable model. It is possible that the
treatments do not change PON1 gene expression or the activity of the enzyme, but instead affect cell
permeability or the cellular transporters that would lead to an increase in PON1 enzyme levels in
serum. In our hands, HepG2 cells did not secrete detectable quantities of the enzyme, excluding its use
as a suitable model for this purpose. Should a fit-for-purpose cultured cell model be available, future
work should focus on the effect of anthocyanins and their metabolites on PON1 enzyme secretion to
ensure that this potential mechanism of actions is also investigated.
In conclusion, the novel data presented in this study do not support the notion that anthocyanins
and/or their metabolites significantly affect PON1 gene promoter activity or change the activities of
PON1 isoenzymes. Even though some statistically significant changes were detected, the changes
were very modest and probably lack clinical importance. However, it is feasible that these compounds
alternatively affect PON1 secretion or interact with different PON1 genotypes rather than those were
reported here, and this should be considered in future studies.
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